

## Special Issue

# Immune Responses to SARS-CoV-2 Vaccines

### Message from the Guest Editors

Although it has been almost three years combating COVID-19, a disease caused by SARS-CoV-2 which has led to more than 6.5 million deaths worldwide, major aspects of the immune response following vaccination and/or infection remain to be fully understood. While multiple vaccines have been established which effectively slowed the pandemic, details of the short- and long-term immunity shaped by vaccines require a more comprehensive evaluation given the narrow timeline set for their development and deployment. Studies of immune responses to SARS-CoV-2 vaccines may guide the improvement of current and future vaccines and provide the immunological framework for eliciting potent responses by vaccination in the event of a future SARS-like coronavirus spillover.

### Guest Editors

Dr. Ge Song

The Scripps Research Institute, La Jolla, CA, USA

Dr. Rami Musharrafieh

The Scripps Research Institute, La Jolla, CA, USA

### Deadline for manuscript submissions

closed (31 August 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/140436](https://mdpi.com/si/140436)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).